Eqis Capital Management Inc. cut its position in shares of Pfizer, Inc. (NYSE:PFE) by 23.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,285 shares of the biopharmaceutical company’s stock after selling 11,184 shares during the period. Eqis Capital Management Inc.’s holdings in Pfizer were worth $1,252,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of PFE. Boston Partners raised its stake in shares of Pfizer by 7.3% during the 1st quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock worth $830,071,000 after purchasing an additional 1,649,801 shares in the last quarter. Bank of Nova Scotia raised its stake in shares of Pfizer by 325.9% during the 1st quarter. Bank of Nova Scotia now owns 1,934,514 shares of the biopharmaceutical company’s stock worth $66,180,000 after purchasing an additional 1,480,258 shares in the last quarter. Fisher Asset Management LLC raised its stake in shares of Pfizer by 3.9% during the 2nd quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock worth $1,143,248,000 after purchasing an additional 1,275,832 shares in the last quarter. State of Tennessee Treasury Department raised its stake in shares of Pfizer by 22.7% during the 1st quarter. State of Tennessee Treasury Department now owns 4,891,784 shares of the biopharmaceutical company’s stock worth $167,348,000 after purchasing an additional 904,413 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. raised its stake in shares of Pfizer by 499.4% during the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 972,122 shares of the biopharmaceutical company’s stock worth $32,654,000 after purchasing an additional 809,933 shares in the last quarter. 68.99% of the stock is owned by institutional investors.
A number of equities research analysts have recently weighed in on PFE shares. Credit Suisse Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $38.00 to $36.00 in a research note on Thursday, July 20th. BMO Capital Markets reaffirmed a “buy” rating and set a $37.00 price target on shares of Pfizer in a research note on Wednesday, September 6th. Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a research note on Friday, July 14th. Vetr downgraded Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target for the company. in a research note on Wednesday, September 13th. Finally, Jefferies Group LLC reaffirmed a “neutral” rating and set a $34.00 price target on shares of Pfizer in a research note on Friday, June 16th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and an average target price of $38.10.
Pfizer, Inc. (PFE) traded down 0.19% during mid-day trading on Thursday, reaching $36.38. The company’s stock had a trading volume of 8,296,189 shares. The stock has a market cap of $216.36 billion, a PE ratio of 26.61 and a beta of 1.00. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $36.60. The company has a 50 day moving average of $35.02 and a 200-day moving average of $33.73.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.64 earnings per share. Equities analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.51%. Pfizer’s dividend payout ratio is 94.12%.
In other Pfizer news, CEO Ian C. Read sold 197,168 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total value of $6,703,712.00. Following the sale, the chief executive officer now owns 580,318 shares in the company, valued at $19,730,812. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock worth $15,813,961 in the last 90 days. Corporate insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.